Drug Landscape ›
Sensodyne Extra Whitening ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 78
Most-reported reactions
Drug Ineffective — 15 reports (19.23%) Oral Discomfort — 14 reports (17.95%) Oral Mucosal Exfoliation — 14 reports (17.95%) Oral Pain — 7 reports (8.97%) Toothache — 7 reports (8.97%) Hyperaesthesia Teeth — 6 reports (7.69%) Product Complaint — 6 reports (7.69%) Coating In Mouth — 3 reports (3.85%) Gingival Pain — 3 reports (3.85%) Mouth Injury — 3 reports (3.85%)
Source database →
Sensodyne Extra Whitening in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Sensodyne Extra Whitening approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Sensodyne Extra Whitening in United States?
Colgate Palmolive is the originator. The local marketing authorisation holder may differ — check the official source linked above.